Aduhelm® (also known as Aducanumab) was recently approved as a treatment for AD (Investor Relations, 2021), the first in more than a decade, but it still focuses on Aβ elimination rather than specific amyloid β oligomer (AβO) targets. The gene discussed is ABO; the disease is Alzheimer disease.